Cezar Iliescu is a Cardiology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 510 publications with 5,972 citations (h-index 34); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304000
Telephone
713-792-6161Provider last certified this registry record 25 Jun 2024.
Clinical trials
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20255 payments
- Impulse Dynamics (USA) Inc.Program year20251 payment
- AngioDynamics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86.2%Beta blocker28.5%Metoprolol Succinate43%Metoprolol Tartrate28%Carvedilol21%Bisoprolol Fumarate8%Part D<11 patientsStatin24%Atorvastatin Calcium56%Rosuvastatin Calcium44%Part D≥24 patients+ 6 more classes in this area
Blood & clotting
11.6%P2Y12 inhibitor6.8%Clopidogrel100%Part D≥15 patientsFactor Xa inhibitor4.8%Eliquis100%Part D≥12 patientsMetabolism & gastrointestinal
2.2%Potassium supplement2.2%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy
European Journal of Heart Failure
2021 - Radiation-Induced Vascular Disease—A State-of-the-Art Review
Frontiers in Cardiovascular Medicine
2021 - Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”